Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Systemic chemotherapy for cholangiocarcinoma].
Furuse J, Suzuki E, Hirokawa S, Kitamura H, Nagashima F. Furuse J, et al. Among authors: nagashima f. Nihon Shokakibyo Gakkai Zasshi. 2010 Jul;107(7):1102-8. Nihon Shokakibyo Gakkai Zasshi. 2010. PMID: 20616478 Review. Japanese. No abstract available.
Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.
Yamashita K, Nagashima F, Fujita K, Yamamoto W, Endo H, Miya T, Narabayashi M, Kawara K, Akiyama Y, Ando Y, Ando M, Sasaki Y. Yamashita K, et al. Among authors: nagashima f. Jpn J Clin Oncol. 2011 Feb;41(2):204-9. doi: 10.1093/jjco/hyq197. Epub 2010 Oct 21. Jpn J Clin Oncol. 2011. PMID: 20965940 Clinical Trial.
[Managements for jaundice].
Furuse J, Toki M, Kitamura H, Hirokawa S, Nagashima F. Furuse J, et al. Among authors: nagashima f. Gan To Kagaku Ryoho. 2011 Apr;38(4):540-4. Gan To Kagaku Ryoho. 2011. PMID: 21498981 Japanese.
Inhibitor of MEK1/2, selumetinib, for biliary tract cancer.
Furuse J, Nagashima F. Furuse J, et al. Among authors: nagashima f. Expert Rev Gastroenterol Hepatol. 2011 Oct;5(5):579-81. doi: 10.1586/egh.11.58. Expert Rev Gastroenterol Hepatol. 2011. PMID: 21910575
Role of chemotherapy in treatments for biliary tract cancer.
Furuse J, Kasuga A, Takasu A, Kitamura H, Nagashima F. Furuse J, et al. Among authors: nagashima f. J Hepatobiliary Pancreat Sci. 2012 Jul;19(4):337-41. doi: 10.1007/s00534-011-0494-2. J Hepatobiliary Pancreat Sci. 2012. PMID: 22456744 Review.
Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival.
Kasuga A, Okano N, Naruge D, Kitamura H, Takasu A, Nagashima F, Furuse J. Kasuga A, et al. Among authors: nagashima f. Cancer Chemother Pharmacol. 2015 Mar;75(3):457-64. doi: 10.1007/s00280-014-2665-8. Epub 2014 Dec 30. Cancer Chemother Pharmacol. 2015. PMID: 25547407
209 results